RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the first quarter ended March 31, 2011. Total product revenue was $105.9 million for the first quarter of 2011, a 140% increase compared to $44.1 million for the first quarter of 2010. XIFAXAN® revenue for the first quarter of 2011 was $80.7 million, a 170% increase compared to $29.9 million for the first quarter of 2010.
